MySubsidy

Production Linked Incentive (PLI) Scheme for Promotion of Domestic Manufacturing of Critical Key Starting Materials (KSMs)/ Drug Intermediates (DIs) and Active Pharmaceutical Ingredients (APIs) in India

Ministry of Chemicals and Fertilizers · Central government

The PLI scheme gives manufacturers financial incentives on incremental sales to boost domestic output of Key Starting Materials, Drug Intermediates and Active Pharmaceutical Ingredients.

Closed. Applications closed on 12 March 2026. The details below describe the most recent cycle.

Key facts

Subsidy amount
Not specified
Instrument
Subsidy
Deadline
12 March 2026
Disbursement
Released against milestones
Scheme duration
121 months

About this scheme

The Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India, runs the Production Linked Incentive (PLI) Scheme for Promotion of Domestic Manufacturing of Critical Key Starting Materials (KSMs)/ Drug Intermediates (DIs) and Active Pharmaceutical Ingredients (APIs) in India. Under the scheme, financial incentives are given on incremental sales of the identified KSMs, DIs and APIs, with the aim of expanding domestic manufacturing capacity for these products. The scheme is intended to lower India's import dependence for these 41 critical pharmaceutical products.

Only greenfield projects qualify, which is meant to draw substantial fresh investment into pharmaceutical manufacturing. The scheme has a total financial outlay of ₹6,940 crore and runs from FY 2020-21 to FY 2029-30, with Financial Year 2019-20 treated as the base year for performance calculations.

The Industrial Finance Corporation of India (IFCI) is the designated Project Management Agency (PMA) and is responsible for implementing and assessing the scheme.

Who can apply

Eligible business forms
Private limited company, Limited liability partnership, One person company, Partnership firm, Sole proprietorship
Udyam registration
Not specified
MSME registration
Not specified
DPIIT startup recognition
Not specified
GST registration
Not specified
Where the business may be based
Not restricted

- Manufacturers of critical KSMs/DIs and APIs registered in India are eligible. - Only greenfield projects (new manufacturing facilities) qualify. - Applicants must meet product-segment-specific threshold investment criteria (e.g., ₹20 crore to ₹400 crore).

How to apply

1. Applications are accepted only in online mode through the dedicated portal: https://plibulkdrugs.ifciltd.com/login. 2. An application fee applies, the amount depending on the eligible product. The fee is ₹1,00,000 for Penicillin G, 7-ACA, Erythromycin Thiocynate (TIOC) and Clavulanic Acid, and ₹50,000 for all other eligible products. 3. Payment of the application fee must be made electronically by NEFT/RTGS to the designated bank account: IFCI – PLI – Bulk Drugs, Account Number: 3859475896, Central Bank of India, IFSC Code: CBIN0281410, Nehru Place Branch, New Delhi - 110019.

Apply on the issuer's site

How applications are assessed

The Project Management Agency (IFCI) will evaluate each application against the details manufacturers furnish. The assessment covers two things: verification of the threshold investment committed to greenfield projects, and an appraisal of the projected incremental sales of the identified KSMs/DIs/APIs.

Statutory Auditor certificates form a critical part of the documentation examined. They are used to confirm compliance with scheme criteria and investment milestones before any incentive is approved and disbursed.

Frequently asked questions

What is the primary objective of the PLI Scheme for Bulk Drugs?

The scheme supports domestic production of Key Starting Materials (KSMs), Drug Intermediates (DIs) and Active Pharmaceutical Ingredients (APIs) in India, with the aim of lowering the country's reliance on imports.

What kind of financial incentives are offered under this scheme?

Manufacturers earn incentives on incremental sales of 41 identified products over 6 years, at rates of 5% to 20% depending on whether the product segment is fermentation-based or chemical synthesis-based and on the financial year.

Who is eligible to apply for this scheme?

Manufacturers of critical KSMs/DIs and APIs registered in India may apply, provided the project is greenfield and meets the threshold investment criteria applicable to its product segment.

What is the total financial outlay and tenure of the scheme?

The scheme's total financial outlay is ₹6,940 crore, and it operates from FY 2020-21 to FY 2029-30, with FY 2019-20 as the base year for calculations.

How does one apply for the PLI Scheme for Bulk Drugs?

Applications are submitted online through the official portal, with a fee of ₹1,00,000 for specific products or ₹50,000 for other eligible products, paid electronically by NEFT/RTGS to the designated IFCI bank account.

What is meant by a 'greenfield project' in the context of this scheme?

A greenfield project is a new manufacturing facility or unit built from scratch, as opposed to an upgrade or expansion of an existing plant, and the scheme supports such new investments in the pharmaceutical sector.

Sectors

  • Health Lifesciences
  • Pharmaceuticals
  • Manufacturing
  • Bulk Drugs
  • Apis
  • Ksms
  • Dis
  • Greenfield Projects
  • Government Scheme

Details last verified on 12 November 2026. Source: the issuer's published information.